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ABSTRACT. We report on the virtual screening, synthesis, and biological evaluation of new furan 
derivatives targeting Mycobacterium tuberculosis salicylate synthase (MbtI). A receptor-based virtual 
screening procedure was applied to screen the Enamine database, identifying two compounds, I and 
III, endowed with a good enzyme inhibitory activity. Considering the most active compound I as 
starting point for the development of novel MbtI inhibitors, we obtained new derivatives based on the 
furan scaffold. Among the SAR performed on this class, compound 1a emerged as the most potent 
MbtI inhibitor reported to date (Ki = 5.3 µM). Moreover, compound 1a showed a promising 
antimycobacterial activity (MIC99 = 156 µM), which is conceivably related to mycobactin biosynthesis 
inhibition. 
 
INTRODUCTION 
Tuberculosis (TB), caused by the pathogen Mycobacterium tuberculosis (Mtb), is one of 
the deadliest infectious diseases worldwide, with about 1.7 million deaths reported in 2016 
[1]. New TB drugs are needed because of the complexity and toxicity of the current TB 
therapeutic regimens and to provide alternatives to contrast the emergence of multidrug-
resistant (MDR) and extensively drug-resistant (XDR) Mtb strains [2,3]. The investigation of 
novel pharmacological targets, such as InhA, MmpL3, DprE1 and QcrB, plays a fundamental 
role in the development of new potential antitubercular agents [4]. Since the most promising 
targets are membrane proteins, the identified hit compounds may also interfere with the 
integrity of the host membranes; therefore, the selection of different targets to be tackled is 
still urgent [5-8]. In addition, there are a number of novel anti-TB compounds in clinical trial, 
and two new drugs have been recently approved: delamanid and bedaquiline. Despite these 
advances, many more TB drug candidates are necessary to sustain an effective and 
productive drug pipeline [9]. In particular, more information on the effectiveness, safety and 
tolerability of bedaquiline is urgently required, because its severe side effects (mainly QT 
prolongation) could be potentially life-threatening [9]. Therefore, the research of new anti-
TB drugs that can shorten and simplify current pharmacological therapy is pivotal [10]. 
One of the strategies adopted to fight bacterial pathogens is to target the biosynthesis of 
mycobactins, high-affinity iron-chelating molecules called siderophores [6]. Iron is an 
essential redox cofactor, involved in several cellular processes, allowing the survival and 
growth of the mycobacterium in the host. Nevertheless, Mtb is capable of sustaining an 
infection even in an iron-deficient environment by overcoming it by means of several iron 
acquisition pathways, among which the synthesis of siderophores plays a key role. Water-
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soluble carboxymycobactins and lipophilic mycobactins, compounds that vary according to 
the nature of their lipophilic moiety, are able to solubilize iron and compete with the iron-
binding proteins (e.g. transferrin, lactoferrin, ferritin) of the host. While mycobactins remain 
associated within the cell wall, carboxymycobactins are released outside the outer 
membrane, where they scavenge iron, making it available for transport into the Mtb 
cytoplasm [11]. As the bacterial strains unable to produce siderophores lose their ability to 
grow within macrophages and sustain the infection [12], there is a considerable interest in 
deciphering the mechanism of siderophore assembly, with the goal of targeting selected 
steps for antitubercular drug development. Among the enzymes involved in siderophore 
biosynthesis [6], the Mg2+-dependent salicylate synthase (MbtI) has been validated as a 
target for fighting TB [13,14]. Since MbtI catalyzes the first step of the process by converting 
chorismate to salicylate via an isochorismate intermediate (Scheme 1), its inhibition leads 
to a reduced mycobacterial pathogenicity without toxicity issues, due to the absence of this 
target in the host [15]. The first structural and biochemical characterization of MbtI was 
reported by Harrison et al. [16] and structural data highlights that the Mg2+ is coordinated by 
E297 and E434, as well as the C1 carboxylate of chorismate [13]. Residue K205 assists the 
attack of water at the chorismate C2 carbon for the isomerization reaction and E252 provides 
acid catalysis for the elimination of the hydroxyl group from C4 carbon. The positioning of 
the pyruvate side chain of the substrate is allowed by the interactions with Y385, R405 and 
G419 [13]. 
 
 
Scheme 1. Reaction catalyzed by MbtI, the salicylate synthase of Mycobacterium tuberculosis. 
 
With the aim of identifying new MbtI inhibitors, a receptor-based virtual screening (VS) 
study was carried out and a preliminary optimization of one of the two identified hits was 
performed. This study has led to novel chemical entities that could represent an alternative 
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and/or complementary therapy for the treatment of multidrug-resistant strains, opening new 
avenues to improved clinical outcomes. 
 
RESULTS AND DISCUSSION 
Virtual Screening. A VS study, focused on the ligand-MbtI key interactions, was 
developed. A pharmacophore model was created based on the analysis of the crystal 
structure of MbtI co-crystallized with 3-(1-carboxyprop-1-enyloxy)-2-hydroxybenzoic acid 
(Methyl-AMT, PDB code 3VEH) [17]. Figure 1A depicts the interactions of Methyl-AMT 
inside the MbtI binding site. The carboxylic group of the 2-hydroxy benzoic acid forms an H-
bond with the side-chain of Y385; the analysis of different MbtI crystal structures suggests 
that the position of this residue is highly conserved, and it is important for the interaction of 
the carboxylic function of the reported MbtI inhibitors. The aromatic ring of the 2-hydroxy 
benzoic acid shows lipophilic interactions with I207, A362, L404 and a cation-π interaction 
with K438. The methyl fragment of the 1-carboxyprop-1-enyloxy ligand chain is inserted into 
a lipophilic pocket mainly delimited by P251, L268, H334 and T361, whereas the second 
carboxylic group shows an ionic interaction involving K438 and it is compatible with the 
interaction with the Magnesium ion. Based on these considerations, we built a structure-
based pharmacophore taking into account a) the H-bond with Y385, b) the lipophilic 
interactions of the aromatic ring, c) the methyl fragment and d) the coordination of the 
carboxylic group with the Magnesium ion. The model, shown in Figure 1B, was generated 
using the software Ligandscout [18] and comprised (1) an H-bond acceptor feature 
representing the oxygen atom of the carboxylic fragment interacting with Y385, (2, 3) two 
hydrophobic features representing the aromatic and methyl substituents and (4) a negative 
feature representing the carboxylic group of the 1-carboxypropenyl-1-enyloxy fragment. In 
addition, the pharmacophore model was refined by adding excluded volume spheres 
mimicking the steric hindrance represented by the MbtI binding site (see Experimental 
Section for more details).  
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Figure 1. (A) Interactions of Methyl-AMT (green) inside the MbtI binding site and (B) receptor-based 
pharmacophore model used for the VS study. 
 
The pharmacophore model was used to screen the Enamine database, comprising about 
1 500 000 commercially available compounds, retrieving only compounds matching all the 
four pharmacophore features and respecting the volume constraints given by the MbtI 
binding site. By applying this strict filter, only 2050 compounds were further considered and 
subjected to docking studies. Recently, we have reported an evaluation of the consensus 
docking approach [19]. Through this approach, one ligand is docked into the target protein 
by means of multiple docking methods. Then, among the best-ranked poses (originated by 
the different docking procedures), the binding pose predicted by the largest number of 
docking methods is considered as the best docking pose. From a qualitative point of view, 
previous results highlighted that consensus docking was able to predict ligand binding poses 
better than the single docking evaluations [20]. Furthermore, concerning the VS studies, the 
results suggested that this approach performed as well as the best available methods found 
in the literature [20], and it was also able to experimentally identify new active molecules 
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[21-23]. The 2050 compounds selected through the pharmacophore filter were subjected to 
a consensus docking protocol calibrated for the docking of MbtI inhibitors. The MtbI-tuned 
consensus docking protocol included 5 different docking methods, i.e. Plants and Gold with 
the four different fitness scoring functions, which were found to be the most reliable 
procedures among a total of 11 different docking methods, according to self-docking studies 
performed on six MbtI-ligand co-crystal structures (see Section S1 of Supplementary 
material for more details). The five selected docking procedures were then applied to the 
2050 commercial compounds. For each ligand, the five docking poses predicted by the five 
docking procedures were clustered together to search for common binding modes. The 
analysis revealed that only 74 compounds presented a binding pose shared by all the five 
docking methods and thus reached the maximum consensus level. Therefore, based on the 
consensus docking filter, only 3.6% of the docked compounds were considered as potential 
active inhibitors. These results are in agreement with our previous consensus docking 
calculations reported in literature, which highlighted the high filtering strictness of this 
procedure. In 2014, we tested the reliability of a consensus docking protocol comprising 10 
different procedures by applying this technique on three different targets of the Directory of 
Useful Decoys (DUD) and at the end of the screening calculations only an average of 0.40% 
of the starting databases was considered as potentially active [19]. More recently, the whole 
DUD dataset has been analyzed by means of the same consensus docking approach and 
an average of 0.44% of the starting databases was considered as potential actives [20]. 
Considering that the higher the number of docking methods included in the consensus 
docking protocol, the higher its filtering strictness, the results obtained with the MtbI-tuned 
consensus docking protocol are in line with those shown by our previous evaluations. The 
analysis of the binding mode predicted for the 74 potential MtbI inhibitors identified by the 
consensus docking protocol revealed that only five compounds still matched the receptor-
based pharmacophore model in their docking pose. On these bases, the five compounds 
were purchased at the highest purity level available from the commercial source (≥ 95%) 
and subjected to biological assays to evaluate their MbtI inhibitory activity. 
MbtI inhibitory activity. Compound effects on MbtI enzyme activity were tested at 
subsaturating concentrations of substrate (chorismic acid, CHA, 50 M), at a final 
concentration of 100 M. The most potent MbtI inhibitors reported in the literature belong to 
the class of the benzimidazole-2-thiones [24] and to the AMT-series, which is structurally 
related to isochorismate [14,15], showing IC50 values of about 10 μM. In particular, Methyl-
AMT, which emerged as the most powerful candidate of the AMT-series, was used as a 
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positive control, showing an IC50 value of 11.6 μM, in agreement with the previously reported 
values [14,15]. As shown in Table 1, one compound was found to be provided with a 
remarkable activity (compound I, IC50 = 21.1 M), another one displayed a modest activity 
(compound III, IC50 = 77.6 M), while the three other compounds resulted completely 
inactive.  
Table 1. In vitro activity of compounds I-V. 
Code Chemical structure 
Residual activity at 
100 μM (%) 
IC50 (µM) 
I 
 
21.3 ± 4.3 21.1 ± 4.1 
II 
 
101.3 ± 3.6 - 
III 
 
38.4 ± 11.4 77.6 ± 5.7 
IV 
 
104.0 ± 13.2 - 
V 
 
108.8 ± 12.0 - 
 
Compounds I and III were also subjected to molecular dynamics (MD) simulations with 
explicit water, in order to further analyze their predicted binding mode. Magnesium ion was 
also included at the entrance of the MbtI active site in order to analyze its interaction with 
the ligands. Figure 2A shows the predicted binding mode of compound I into the MbtI binding 
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site. The Magnesium ion presents an octahedral coordination geometry: it is bound by a 
water molecule, one oxygen of the carboxylate groups of E294, E297 and E434 and the two 
oxygens of the carboxylate of compound I. The furan ring shows an H-bond with K438, 
whereas the benzene ring, as for Methyl-AMT, exhibits lipophilic interactions with I207, L404 
and a cation-π interaction with K438. Finally, the nitro group strongly interacts with Y385 
and, furthermore, it forms a second H-bond with the nitrogen backbone of R405. Figure 2B 
shows the average minimized structure of the MtbI-III complex. The two oxygens of the 
carboxyl group of the compound interact with the Magnesium ion, the benzoic acid ring 
shows lipophilic interactions with I207, whereas the 2-methoxy-5-nitrophenyl fragment loses 
the H-bond with the hydroxyl group of Y385 during the initial steps of the MD. However, the 
loss of the H-bond with Y385 could be partially compensated with the presence of H-bonds 
between the sulfonamide group and the backbone oxygen of T361 and the side chain of 
K438. 
 
Figure 2. Minimized average structures of I (A) and III (B) docked into MbtI binding site. 
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In order to further assess the solidity of our VS workflow, a retrospective evaluation was 
carried out. In particular, as shown in Supplementary material (Sections S2, S3) simpler 
ligand-based approaches such as fingerprint similarity searches or 3D ligand similarity 
screenings showed a lower performance in retrieving the most active identified compound 
(I) from the initial commercial database. Moreover, as shown in Supplementary material 
(Section S4), the application of the consensus docking approach was found to outperform 
the single docking methods in identifying compound I from the 2050 ligands selected through 
the pharmacophore filter.  
Structure-activity relationship (SAR) studies. In this study we considered the most 
active compound I as starting point for the development of novel MbtI inhibitors to obtain 
new derivatives showing potent in vitro inhibition. In order to support the importance of each 
pharmacophoric feature disclosed by the modeling studies, we designed and synthesized 
analogs to explore the chemical space and to study the structural and functional 
requirements for the activity against MbtI. We took into account two main points, namely the 
substitutions at the phenyl ring and the acidic moiety; the results are summarized in Table 
2. By alternatively removing the chlorine atom or the para nitro group from I, we obtained 
the active derivative 1a and the inactive compound 1b, respectively. When both these 
substituents were removed (1c), a complete loss of activity was detected. The replacement 
of the phenyl ring with pyridine (1d) afforded a partially active compound. The corresponding 
isomeric derivatives having the nitro substituent in meta (1e) and in ortho (1f) positions lost 
potency, both inhibiting MbtI activity by  ̴ 50%, at a concentration of 100 M. The inactive 
compound 1g, bearing in para position of the phenyl ring a group unable to simultaneously 
accept two hydrogen bonds in the suitable geometry, supported the hypothesized binding 
mode for this class of compounds; likewise, the substitution of the nitro group with the CF3 
group (1h) led only to a retention of a modest activity (66% residual activity). As a further 
attempt, the para-nitro group of 1a was replaced with the methylsulfonyl (1i) and 
sulfonamide (1j) substituents. With respect to the nitro moiety, they are larger fragments; 
however, they could potentially interact through two H-bonds with the protein by means of 
the two oxygens, as the nitro moiety. In the first case, the replacement resulted in complete 
loss of activity, whereas compound 1j retained a low activity (84% residual activity). The 
substitution of the para-nitro group with other bioisosteres led to weak (1k,l) or inactive (1m-
o) compounds. In order to assess if the carboxylic group linked to the furan conferred 
potency in the most active candidate 1a, the corresponding ester derivative (2a) was tested 
and it was found to be only slightly active (71% residual activity), thus confirming the 
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importance of the interaction between this function and MbtI. Finally, when the furan was 
substituted with a phenyl moiety (3) a partial activity was observed, while the removal of the 
furan led to an inactive compound (4).  
 
Table 2. In vitro activity of compounds 1a-o, 2a, 3,4. 
 
code R1 R2 
Residual activity at 100 M 
(%) 
1a 4-NO2-Ph H 18.2 ± 5.1 
1b 2-Cl-Ph H 92.4 ± 13.8 
1c Ph H 102.0 ± 8.5 
1d 
 
H 45.0 ± 5.1 
1e 3-NO2-Ph H 50.2 ± 13.0 
1f 2-NO2-Ph H 55.1 ± 22.7 
1g 4-OH-Ph H 96.3 ± 19.2 
1h 4-CF3-Ph H 66.3 ± 9.7 
1i 4-SO2CH3-Ph H 98.5 ± 14.4 
1j 4-SO2NH2-Ph H 84.6± 16.2 
1k 
 
H 46.8 ± 8.3 
1l 
 
H 58.0 ± 8.9 
1m 4-CN-Ph H 125.6 ± 17.9 
1n 4-COOH-Ph H 92.4 ± 11.8 
11 
 
1o 
 
H 104.4 ± 7.8 
2a 4-NO2-Ph CH3 71.1 ± 18.4 
3 
 
36.8 ± 7.6 
4 
 
89.3 ± 16.1 
 
The SAR studies allowed to evidence that compound 1a shows an improved potency with 
respect to our initial hit I, as it displayed an IC50 value of 7.6 ± 1.6 μM (Figure 3A). Moreover, 
the MbtI kinetic analysis in the presence of 1a proved that this compound is a potent 
competitive inhibitor towards the chorismate binding site, displaying a Ki value of 5.3 ± 0.6 
μM (Figure 3B and 3C). 
 
 
Figure 3. Effects of the compounds against MbtI enzyme activity. (A) Graph comparing I (▼) and Methyl-
AMT () with 1a (). IC50 values were determined at subsaturating concentrations of CHA (50 M). (B) Steady 
state kinetics analysis towards CHA of MbtI in the presence of different concentrations of 1a (0, 5, 10, 20, 50 
and 100 M) highlights the competitive behavior of the inhibitor. (C) Global reciprocal plot of data in panel B. 
All data are mean SD of three replicates. 
 
12 
 
Mtb minimal inhibitory concentration determination (MIC99). In order to assess its 
potency, the inhibitor 1a was investigated for its antibacterial activity against M. tuberculosis 
H37Rv, together with 2a, on the basis of the higher activity of esters with respect to the 
carboxylic acids on this parasite, probably owing to a better ability to cross the mycobacterial 
cell wall [15]. Compound 1a showed a MIC99 of 156 µM, whereas for 2a we did not detect 
an improvement of the cellular potency, probably due to its low solubility in the assay 
medium. It is noteworthy that, to the best of our knowledge, 1a can be considered as one of 
the MbtI inhibitors showing the best antimycobacterial activity.  
Mycobactin biosynthesis inhibition. To assess if the antitubercular activity is indeed 
related with iron-uptake inhibition, we used the non-pathogenic M. bovis BCG, whose 
siderophores closely resemble the structure of Mtb mycobactins [26,27]. The compound, 
when assayed against cells grown in the low iron containing Chelated Sauton’s medium, 
showed a MIC value 3-fold lower than against mycobacteria grown in 7H9 medium (80 μM 
vs 240 μM), suggesting that the mechanism of action of 1a involves iron uptake. Thus, in 
order to support the correlation of the antitubercular activity of 1a with MbtI inhibition, the 
effects of the compound on siderophore production were assessed in M. bovis BCG cells, 
grown in iron-depleted medium and in the presence of different sub-lethal concentrations of 
compound 1a. To this purpose, the levels of siderophore production were measured using 
Universal CAS liquid assay [28] and through the mycobactins isolation and quantification. 
As shown in Figure S94, the CAS assay performed on the medium of the cells grown in 
different concentrations of 1a, showed a removal of iron inversely related to the 
concentration of the compound. Similarly, the concentration of mycobactins, determined in 
the same cells, decreased at higher concentrations of 1a, confirming that the inhibitory effect 
towards Mtb growth could be due to mycobactin biosynthesis inhibition.  
Chemistry. Compounds 1a,e and 4 were purchased and their purity was assessed using 
HPLC (≥ 95%). Details are provided in Supplementary material. The methyl ester (2a) of 1a, 
as well as compounds 5 and 6, were obtained according to a common procedure (Fischer-
Speier esterification). Compounds 1b-d,f-o, 3 were synthesized by a Suzuki-Miyaura 
coupling reaction [29], followed by a base-catalyzed hydrolysis of the ester function. The 
synthetic pathways are reported in the Scheme 2, the general procedures are described in 
the experimental section, while all the details concerning the specific synthetic steps and 
the analytical data are provided in Supplementary material. 
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Scheme 2. Reagents and conditions: (a) conc. H2SO4, CH3OH, reflux, 24 h; (b) i-PrMgCl, Bis[2-(N,N-
dimethylamino)ethyl]ether, B(OCH3)3, THF, 15°C 20 min → 20°C, 30 min → 0°C, 10 min, N2; (c) appropriate 
reagent, Pd(PPh3)2Cl2, 2M Na2CO3, 1,4-dioxane, 90°C, overnight, N2, (for 2k,l,o 60°C, 1 h, M.W.); (d) 1M 
NaOH, CH3CH2OH/THF 1:1, reflux, 5 h (for 1d: LiOH·H2O THF/H2O, 20°C, 2 h; for 1l: 0.5M NaOH, 
CH3CH2OH/THF 1:1, 20°C, 30 min); (e) KOH, H2O, reflux, 6 h. 
 
CONCLUSIONS 
MbtI is a validated and attractive target for the treatment of tuberculosis, and its inhibition 
leads to a reduced mycobacterial pathogenicity without toxicity issues, due to the absence 
of this target in the host. Starting from the computational analysis of the interaction between 
Entry R1 Entry R1 
1,2b 2-Cl-Ph 1,2j 4-SO2NH2-Ph 
1,2c Ph 1,2k 
 
1,2d 
 
1,2l 
 
1,2f 2-NO2-Ph 1,2m 4-CN-Ph 
    
1,2g 4-OH-Ph 1n 4-COOH-Ph 
1,2h 4-CF3-Ph 1,2o 
 
1,2i 4-SO2CH3-Ph 3,7 4-NO2-Ph 
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MbtI and methyl-AMT, a VS study was carried out, identifying the hit compounds I and III as 
interesting inhibitors. Considering the most active compound I, we described the synthesis 
and biological evaluation of new MbtI inhibitors, based on the furan scaffold and having 
different substituents on the phenyl ring. Initial SAR studies applied on I allowed the 
identification of a potent competitive MbtI inhibitor, compound 1a. Remarkably, 1a exerts a 
slightly better in vitro inhibitory activity (IC50 = 7.6 μM) compared to Methyl-AMT (IC50 = 11.6 
μM), which is the best MbtI inhibitor discovered to date. In addition, 1a displayed a MIC99 
value of 156 μM, currently being the first potent MbtI inhibitor endowed with a promising 
antitubercular activity. In addition, siderophore assay suggested that the inhibitory effect of 
1a towards Mtb growth could be due to mycobactin biosynthesis inhibition, thus highlighting 
the importance of this pathway as target for the development of therapeutic interventions. It 
is noteworthy that compound 1a contains a nitrophenyl moiety as a bioisoster of the salicylic 
moiety of Methyl-AMT. Even if the nitro group is a cause for concern in medicinal chemistry, 
for the first time we demonstrated the effective replacement of one carboxylic group of 
Methyl-AMT without loss of MbtI inhibitory potency, allowing, at the same time, a better 
permeability through the Mtb cell wall. Our results are the starting point to expand the SAR 
study among this class of derivatives, exploiting other hitherto unconsidered 
pharmacophoric features, with the aim of disclosing new lead compounds lacking the nitro 
group, making our series more attractive for further developments. 
 
In conclusion, the analysis of the hypothetical binding mode of this class of compounds 
suggested potential points of modification that led to significant developments, and that 
could be further explored to increase the potency of these derivatives.  
 
EXPERIMENTAL SECTION: 
Pharmacophore model generation. One of the main drawbacks of the VS consensus 
docking approach is the required computing time, because by using this method a whole 
data set of molecules should be subjected to different docking procedures [19]. Therefore, 
in order to reduce the number of compounds to be analyzed, a pharmacophore screening 
was used as a prefilter. The pharmacophore hypothesis was built on the basis of the 3D 
structure of MbtI co-crystallized with methyl-AMT (PDB code 3VEH) [17]. The software 
LigandScout 4.08 [18] was used for the creation of the receptor-based pharmacophore 
models. An exhaustive pharmacophore model including all the possible features identified 
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by the program was generated and, subsequently, only the desired features were retained 
in the final pharmacophore model, for a total of four features. The excluded volume spheres 
were defined on the basis of the receptor structure as implemented in the default 
LigandScout configuration. 
Database Generation and Pharmacophore Screening. The Enamine database, 
comprising about 1 500 000 commercially available compounds was used as the screening 
database. The idbgen-gui utility of LigandScout was employed to create the LigandScout 
3D database. The iCon Best conformational sampling method was applied. The 3D 
database was then screened using the previously created receptor-based pharmacophore 
model and the receptor excluded volume, imposing that only the compounds matching all 
the four pharmacophoric features of the model were retrieved. 
Docking procedures and pose filtering. Prior to the docking analysis, a self-docking 
evaluation of the main MbtI-inhibitor X-ray complexes (PDB codes 3RV6, 3RV7, 3RV8, 
3RV9, 3ST6 and 3VEH) was carried out using Autodock, Autodock vina, Dock, Fred, Gold 
with the four fitness functions implemented (i.e., GoldScore, ChemScore, Astex Statistical 
Potential and ChemPLP), Glide with the standard and extra precision methods and Plants. 
The use of Gold, with the four different fitness functions, and Plants resulted to be the most 
reliable ones as they showed an average RMSD lower than 2.0 Å. For all the docking 
procedures the region of interest for the docking studies was defined in such a manner that 
it contained all residues that stayed within 10 Å from the ligand in the X-ray structure.  
Gold. The ‘‘allow early termination’’ command was deactivated, while the possibility for the 
ligand to flip ring corners was activated. For all other parameters, Gold defaults were used 
and the ligands were subjected to 30 genetic algorithm runs. Four docking analyses were 
carried out, corresponding to the four implemented fitness functions.  
Plants. This docking software uses Ant Colony Optimization, a state-of the-art global 
optimization algorithm to find minima of a scoring function representing favorable complex 
structures [30,31]. ChemPLP scoring function was employed to score protein-ligand 
interactions as well as intra-ligand clash terms. Standard settings for all parameters were 
used for the scoring function and the optimization algorithm (search speed setting: 
‘‘speed1’’). 
Consensus docking evaluation. By applying the five docking methods, five different binding 
dispositions (best-scored docking pose) resulted from the docking of each ligand into each 
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protein binding site. The RMSD of these docking poses against the remaining four was 
evaluated by using the rms_analysis software of the Gold suite. On this basis, for each 
ligand docked into the protein binding site, a 5 × 5 matrix was generated reporting the RMSD 
results. By using an in-house program [18], these results were clustered, so that among the 
five results, all of the similar docking poses were clustered together. As a clustering 
algorithm, we used the complete-linkage method, which is an agglomerative type of 
hierarchical clustering. We selected an RMSD clustering threshold of 2.0 Å; therefore, the 
so-obtained clusters contained the group of poses that were less than 2.0 Å away from all 
others poses belonging to the same cluster. All of the ligands showing a consensus level of 
five were taken into account. 
Filtering of docking results. The filtering of the docking results was carried out by 
superimposing the docked compounds to the pharmacophore directly from the supplied 
poses, without changing their coordinates. The retrieval of compounds matching all the four 
pharmacophoric features of the model was imposed in this search. 
MD simulations. All simulations were carried out using AMBER 14 [32]. MD simulations 
were performed using the ff14SB force field at 300 K. The complex was placed in a 
rectangular parallelepiped water box. Magnesium ion was inserted analyzing its disposition 
and interaction into the 2FN1 PDB code [33]. Many force field-based MD simulations of 
biological systems containing Mg2+ have already been reported in literature [34-37]. In the 
present study we used the particle mesh Ewald (PME) compatible Lennard-Jones 
parameters for divalent metal ions in explicit solvent reported by Merz and co-workers [38]. 
An explicit solvent model for water, TIP3P, was used, and the complexes were solvated with 
a 20 Å water cap. Sodium ions were added as counterions to neutralize the system. Prior to 
MD simulations, two steps of minimization were carried out; in the first stage, we kept the 
protein fixed with a position restraint of 500 kcal/mol•Å2 and we solely minimized the 
positions of the water molecules. In the second stage, we minimized the entire system 
through 5000 steps of steepest descent followed by conjugate gradient (CG) until a 
convergence of 0.05 kcal/Å•mol, using the same procedure described above. PME 
electrostatics and periodic boundary conditions were used in the simulation [39]. The MD 
trajectory was run using the minimized structure as the starting conformation. The time step 
of the simulations was 2.0 fs with a cutoff of 10 Å for the non-bonded interaction, and SHAKE 
was employed to keep all bonds involving hydrogen atoms rigid. Constant-volume periodic 
boundary MD was carried out for 0.5 ns, during which the temperature was raised from 0 to 
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300 K. Then 19.5 ns of constant pressure periodic boundary MD was performed at 300 K 
using the Langevin thermostat to maintain constant the temperature of our system. All the α 
carbons of the protein were blocked with a harmonic force constant of 10 kcal/mol•Å2 for the 
first 3.5 ns while in the last 16.5 ns no constraints were applied. General Amber force field 
(GAFF) parameters were assigned to the ligands, while partial charges were calculated 
using the AM1-BCC method as implemented in the Antechamber suite of AMBER 14. 
General Synthetic Procedures and Materials. Commercial products (1a,e and 4), 
chemicals and solvents were of reagent grade; they were purchased from suppliers (Sigma-
Aldrich) and used as received. Anhydrous solvents were utilized without further drying. 
Aluminum backed Silica Gel 60 plates (0.2 mm, Merck) were used for analytical TLC, to 
follow the course of the reaction. Silica gel 60 (Merck 40–63 μm) was used for the purification 
of intermediates and final compounds, through flash column chromatography. Melting points 
were determined in open capillary tubes with a Büchi Melting Point 510. All tested 
compounds were characterized by the means of FT-IR, 1H NMR, 13C NMR, MS and HPLC 
to check their purity. 1H and 13C NMR spectra were acquired at ambient temperature with a 
Varian-Oxford 300 MHz instrument, operating at 300 MHz for 1H and 75 MHz for 13C. 
Chemical shifts are expressed in ppm (δ) from tetramethylsilane resonance in the indicated 
solvent (TMS: δ = 0.0 ppm), while J-couplings are given in Hertz. The APT sequence was 
used when deemed necessary. IR spectra were acquired with a Perkin Elmer Spectrum One 
FT-IR in a spectral region between 4000 and 450 cm-1 and analyzed by transmittance 
technique with 32 scansions and 4 cm-1 resolution. Solid samples were mixed in a mortar 
with KBr (1:100) and pressed, using a hydraulic press (14 tons), to small tablets. MS 
analyses were carried out with a Thermo Finnigan (MA, USA) LCQ Advantage system, 
equipped with a quaternary pump, a Diode Array Detector (working wavelength: 254 nm) 
and a MS spectrometer, with an Electrospray ionization source and an Ion Trap mass 
analyzer (ionization: ESI positive or ESI negative; capillary temperature: 250°C; source 
voltage: 5.50 kV; source current: 4.00 µA; multipole 1 and 2 offset: -5.50 V and -7.50 V, 
respectively; intermultipole lens voltage: -16.00 V; trap DC offset voltage: -10.00 V). The 
purity of the compounds was assessed by means of HPLC ( = 220 nm) and was ≥ 95% 
unless otherwise stated. Column: EVO C18 Phenomenex. Eluent system: aqueous formic 
acid (0.05%) / acetonitrile 50:50. Total flow: 1.2 mL/min. Injection volume: 30 µL. 
Compounds I-V were purchased from Enamine at the highest purity level available (≥ 95 
%). 
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Details about specific synthetic procedures and analytical data (Table S2) of compounds 
1a-o, 2a, 3 and 4 are reported in Supplementary material. 
 
Procedure A for the synthesis of compounds 2b-d,f-j,m and 7. 
Methyl 5-bromofuran-2-carboxylate (5, 1 mmol), the appropriate phenylboronic acid (1.3 
mmol) and bis(triphenylphosphine)palladium(II) dichloride (5% mol) were dissolved in dry 
1,4-dioxane (10 mL), under nitrogen atmosphere. A 2M sodium carbonate solution (2 mmol) 
was then added and the resulting mixture was stirred overnight at 90°C. After completion, 
the solution was cooled to room temperature and then filtered on a celite pad. The filtrate 
was diluted with water and extracted with ethyl acetate (3 x 4 mL). The organic layer was 
dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. Compound 7 was 
obtained from methyl 3-bromobenzoate (6, 1 mmol) and 4-nitrophenylboronic acid (1.3 
mmol) following the same procedure. 
Procedure B for the synthesis of compounds 2k,l,o.  
Methyl 5-boronofuran-2-carboxylate (8, 1.3 mmol), the appropriate bromo derivatives (10, 
or 12, or 13, 1.0 mmol) and bis(triphenylphosphine)palladium(II) dichloride (5% mol) were 
dissolved in dry 1,4-dioxane (10 mL), under nitrogen atmosphere. A 2M sodium carbonate 
solution (2 mmol) was then added and the resulting mixture was stirred in a microwave 
synthesizer (Biotage Initiator Classic) for 1 h at 60°C. After completion, the solution was 
cooled to room temperature and then filtered on a celite pad. The filtrate was diluted with 
water and extracted with ethyl acetate (3 x 4 mL). The organic layer was dried over 
anhydrous sodium sulfate, filtered and concentrated in vacuo. 
Procedure C for the synthesis of compounds 1b-d,f-o and 3. 
The appropriate methyl ester derivative (2b-d, f-m, o, 7, 1 mmol) was dissolved in a 
mixture of tetrahydrofuran – ethanol 1:1 (15 mL) and a 1M solution of sodium hydroxide (2.5 
mmol) was added dropwise while stirring. The reaction mixture was heated at reflux for 5 h. 
After completion, the solvent was evaporated under reduced pressure; the aqueous phase 
was washed with chloroform (1 x 5 mL), acidified with hydrochloric acid (3M) and then 
extracted with ethyl acetate (3 x 7 mL). The organic layers were washed with brine, dried 
over anhydrous sodium sulfate and then concentrated in vacuo. The resulting solid was 
finally washed with cool hexane (3 mL). Variations to this general procedure were applied 
to the synthesis of 1d,l (see Supplementary material for details). 
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Compound 1m (1 mmol) was further treated with potassium hydroxide (4.5 mmol) in water 
(12 mL) at reflux for 6 h. After completion, the solution was acidified with hydrochloric acid 
(10M) and then extracted with ethyl acetate (3 x 7 mL). The organic layers were washed 
with brine, dried over anhydrous sodium sulfate and then concentrated in vacuo to obtain 
1n as a light yellow solid. 
Characterization of 1a-o, 2a, 3, 4. All compounds were characterized using 1H NMR,13C 
NMR, MS, IR spectroscopy, and RP-HPLC. The purity was ≥ 95% according to analytical 
RP-HPLC. 1H NMR and 13C NMR spectra, together with RP-HPLC chromatograms are 
provided in Supplementary material. 
Production and purification of chorismic acid. Chorismic acid was produced using the 
Escherichia coli KA12 strain, according to Grisostomi et al. [40] and purified by a modified 
protocol described in Supplementary material. 
MbtI Expression, Purification and Inhibition assays. Rv2386c gene, encoding the MbtI 
was cloned into pET28b expression vector, and the protein was expressed in BL21 (DE3) 
E. coli cells and purified as reported in Supplementary Information. Enzymatic activity was 
determined at 37 °C by L-lactic coupled assay, as previously described [14]. The standard 
reaction mixture contained 50 mM HEPES pH 8.0, 0.2 mM NADH, 10 mM MgCl2, 3 units of 
L-lactic dehydrogenase (Sigma Aldrich), 10-20 μM MbtI, and the reactions were started by 
the addition of the substrate (CHA). Steady-state kinetic parameters were determined by 
assaying the enzyme at variable concentrations of chorismic acid (10-500 μM). The 
experiments were performed in triplicate, and the kinetic constants Km and kcat determined 
by fitting the data to the Michaelis-Menten equation using Origin 8 software. Initially, MbtI 
inhibition was screened for all compounds at 100 µM (dissolved in a solution containing 10% 
DMSO) and 50 μM chorismic acid. The compound solubility in the medium assay was 
verified up to 100 μM concentration. For compounds that significantly inhibited the enzyme 
activity, IC50 and Ki values were determined. For IC50 determinations, the enzyme activities 
were measured in the presence of compound and values were estimated according to the 
Equation 1, where A[I] is the enzyme activity at inhibitor concentration [I] and A[0] is the 
enzyme activity without inhibitor. 
A[I]=A[0]× (1-
[I]
[I]+IC50
)  Equation 1 
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The inhibition constant (Ki) values were determined by assaying the MbtI enzymatic activity 
at different substrate and compound concentrations, using an adapted equation for 
competitive inhibition (Equation 2) with Origin 8 software.  
v= 
Vmax[S]
[S]+ Km(1+
[I]
Ki
)
 Equation 2 
Pan Assay Interference Compounds (PAINS) analysis. As reported by Baell and 
Holloway, there is a number of substructural features which could help to identify 
compounds that appear as PAINS in many biochemical high-throughput screens [41,42]. 
The corresponding filters have been included in the Filter-itTM software and compound 1a 
was thus filtered by using this program. The result highlighted that this compound did not 
possess any of the substructural features shared by the most common PAINS. Moreover, 
to verify the possible formation of aggregates, the ability of compound 1a to inhibit MbtI 
activity was also tested in the presence of 0.1 mg/mL of bovine serum albumin (BSA) or in 
the presence of 0.01% (v/v) Triton X-100 as detergent [43]. As reported in Figure S93, the 
IC50 value in the presence of BSA (7.28 ± 1.41 μM) or in the presence of Triton X-100 (8.00 
± 1.28 μM) are not significantly different, supporting the notion that the ligand did not act as 
an aggregate. Finally, to exclude a promiscuous enzyme inhibition due to covalent reaction 
with cysteines [44]. MbtI inhibition activity of compound 1a was also tested in the presence 
of 100 M of 1,4-dithio-DL-threitol (DTT). As depicted in Figure S93, the IC50 was not 
influenced by DTT (7.84 ± 1.07 μM), thus excluding an interaction of 1a with the MbtI 
cysteines. 
Minimal inhibitory concentration determinations. The MIC99 of 1a and 2a, against M. 
tuberculosis H37Rv, was determined in solid medium. A single colony was inoculated in 
complete Middlebrook 7H9 supplemented with 10% OADC Middlebrook Enrichment, and 
grown at 37 °C until exponential growth phase (~108 CFU/mL). Dilutions to the final 
concentration of ~106 CFU/mL were performed and about 1 µL of cell culture was streaked 
onto plates containing two-fold serial dilutions of appropriate compound. MIC values were 
assigned as the lowest drug concentrations inhibiting bacterial cell growth. The experiments 
were performed in triplicate. Additionally, the compound was assayed against M. bovis BCG 
in liquid medium, in high and low iron media, by determining the MIC against cells grown 
both in 7H9/OADC medium and in low-iron Chelated Sauton’s medium [45].  
Siderophore production assay. Siderophore activity present in the culture was tested in 
M. bovis BCG through the isolation of mycobactins [46] or using the Universal CAS liquid 
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assay [28]. To this purpose, M. bovis was grown in 7H9 medium, subcultured in chelated 
Sauton’s medium, then diluted 1:1000 in chelated Sauton’s containing different 
concentrations of compound 1a. After 15 days of incubation at 37°C, cells were harvested 
by centrifugation. For the isolation of mycobactins, cell pellets were extracted in ethanol 
overnight. 0.1 M FeCl3 in ethanol was added until no further change in colour was observed, 
and the mixture incubated at room temperature for 1 h. Mycobactins were then extracted in 
chloroform, washed with water 3 times to remove the excess of iron, and evaporated. 
Residue was dissolved in methanol. The concentration of mycobactins was determined by 
measuring the absorbance at 450 nm (1% solution of mycobactins gives an absorbance of 
42.8) [46]. For Universal CAS assay 100 l of cell cultures supernatant was mixed with 100 
l of CAS assay liquid solution in 96 well plate, incubated 10 min at room temperature, then 
the absorbance was measured at 630 nm. The siderophore units were calculated using the 
following equation 
Ar-As
Ar
× 100 Equation 3 
where Ar is the absorbance at 630 nm of the blank medium with CAS assay solution and As 
is the absorbance of the culture supernatants with CAS assay solution.  
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